Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014 (2014), Article ID 975178, 14 pages
http://dx.doi.org/10.1155/2014/975178
Review Article

Adiponectin as a Biomarker of Osteoporosis in Postmenopausal Women: Controversies

1Department of Functional Diagnostics and Physical Medicine, Faculty of Health Sciences, Pomeranian Medical University in Szczecin, ul. Grudziądzka 31, 70-103 Szczecin, Poland
2Department of Physiology, Faculty of Natural Sciences, Szczecin University, ul. Felczaka 3c, 71-412 Szczecin, Poland
3Institute of Physical Culture, Faculty of Physical Education, Health, and Tourism, Kazimierz Wielki University in Bydgoszcz, ul. Jana Karola Chodkiewicza 30, 85-064 Bydgoszcz, Poland
4Chair and Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, al. Powstańców Wlkp. 72, 70-111 Szczecin, Poland

Received 30 June 2013; Revised 22 October 2013; Accepted 22 October 2013; Published 23 January 2014

Academic Editor: Ferdinando Mannello

Copyright © 2014 Anna Lubkowska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The literature reports indicating a link between plasma levels of adiponectin and body fat, bone mineral density, sex hormones, and peri- and postmenopausal changes, draw attention to the possible use of adiponectin as an indicator of osteoporotic changes, suggesting that adiponectin may also modulate bone metabolism. In this study, we attempted to analyze the available in vitro and in vivo results which could verify this hypothesis. Although several studies have shown that adiponectin has an adverse effect on bone mass, mainly by intensifying resorption, this peptide has also been demonstrated to increase the proliferation and differentiation of osteoblasts, inhibit the activity of osteoclasts, and reduce bone resorption. There are still many ambiguities; for example, it can be assumed that concentrations of adiponectin in plasma do not satisfactorily reflect its production by adipose tissue, as well as conflicting in vitro and in vivo results. It seems that the potential benefit in the treatment of patients with osteoporosis associated with the pharmacological regulation of adiponectin is controversial.